DBV Technologies S.A. American Depositary Shares DBVT
Analyst Ratings
- Consensus
- Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $45.25 (+401.7% upside)
Key Stats
- Today's Range
- $9.00 – $9.47
- 50-Day Range
- $8.63 – $12.73
- 52-Week Range
- $8.63 – $26.18
- Volume
- 156K shs
- Average Volume
- 359K shs
- Market Cap
- $566.82 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.06%
- Days to Cover
- 4.17
About DBV Technologies S.A. American Depositary Shares
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Related Stocks
Compare head-to-head: DBVT vs AMGN·DBVT vs MRNA·DBVT vs RGEN·DBVT vs HALO
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.
